Dual orexin receptor antagonists (DORAs) prolong total sleep time (TST) and enhance sleep efficiency (SE) without impairing respiratory function among patients with obstructive sleep apnea (OSA).
Tissue Penetration: Consistent with the recently updated trial protocol, tissue Css levels were evaluated in addition to plasma Css levels. The 80 mg/day dose, in both treatment arms, achieved tissue ...